What is Prolacta Bioscience?
Founded in 1999 and headquartered in Duarte, California, Prolacta Bioscience is a privately held life sciences enterprise dedicated to the development of 100% human milk-based nutritional products. By focusing on the unique biological properties of human milk, the company addresses critical nutritional needs in neonatal intensive care units. Prolacta's market position is defined by its proprietary processing technologies and its role as a vital partner to hospitals seeking to improve patient outcomes through evidence-based nutrition. The company operates at the intersection of biotechnology and clinical nutrition, leveraging rigorous scientific standards to transform human milk into life-saving therapeutic products.
How much funding has Prolacta Bioscience raised?
Prolacta Bioscience has raised a total of $73.6M across 6 funding rounds:
Series A
$811K
Series B
$5M
Series C
$12M
Private Equity
$5.8M
Series D
$15M
Private Equity
$35M
Series A (2004): $811K, investors not publicly disclosed
Series B (2006): $5M led by Arcturus Capital, Mercury Fund, Gideon Hixon Fund, and Funk Ventures Capital
Series C (2007): $12M supported by Funk Ventures, DFJ Mercury, DFJ Frontier, Alta Partners, and Gideon Hixon Fund
Private Equity (2011): $5.8M, investors not publicly disclosed
Series D (2011): $15M backed by Health Evolution Partners
Private Equity (2016): $35M, investors not publicly disclosed
Key Investors in Prolacta Bioscience
Funk Ventures
Funk Ventures is a multi-faceted private equity firm based in Los Angeles that provides value-add investments across technology, wellness, and interactive gaming sectors.
DFJ Mercury
A prominent venture capital firm with a global reach, focused on identifying and backing extraordinary entrepreneurs who are building industry-changing companies.
Alta Partners
A specialized venture capital firm with a deep focus on healthcare and life sciences, dedicated to supporting innovative companies that enhance patient outcomes.
What's next for Prolacta Bioscience?
Looking ahead, Prolacta Bioscience is well-positioned to leverage its recent capital injection to expand its clinical footprint and enhance its product pipeline. The company's strategic roadmap likely involves scaling its manufacturing capabilities to meet the rising demand for specialized neonatal nutrition while continuing to invest in clinical research that validates the efficacy of its human milk-based offerings. As the firm matures, the focus will remain on maintaining its competitive advantage through innovation and strategic partnerships within the healthcare ecosystem. By prioritizing high-impact clinical outcomes, Prolacta is poised to further solidify its leadership in the life sciences market, potentially exploring new therapeutic applications for its proprietary technology platform.
See full Prolacta Bioscience company page
